Evidence map›Paper›PMID 31533894›Full record

ArticleThe lancet. HIV2019

Impact of combination HIV interventions on HIV incidence in hyperendemic fishing communities in Uganda: a prospective cohort study.

Joseph Kagaayi, Larry W Chang, Victor Ssempijja, M Kate Grabowski, Robert Ssekubugu, Gertrude Nakigozi, Godfrey Kigozi, David M Serwadda, Ronald H Gray, Fred Nalugoda and 13 more

Abstract read
In one paragraph

Article in The lancet. HIV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
20.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Incidence of Health Facility Switching and Associations With HIV Viral Rebound Among Persons on Antiretroviral Therapy in Uganda: A Population-based Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 3 countries.

Joseph KagaayiRakai Health Sciences Program, Entebbe, Uganda; Makerere University School of Public Health, Kampala, Uganda.
Larry W ChangRakai Health Sciences Program, Entebbe, Uganda; Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Social and Behavioral Interventions Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: lchang8@jhmi.edu.
Victor SsempijjaClinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, MD, USA.
M Kate GrabowskiRakai Health Sciences Program, Entebbe, Uganda; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Robert SsekubuguRakai Health Sciences Program, Entebbe, Uganda.
Gertrude NakigoziRakai Health Sciences Program, Entebbe, Uganda.
Godfrey KigoziRakai Health Sciences Program, Entebbe, Uganda.
David M SerwaddaRakai Health Sciences Program, Entebbe, Uganda; Makerere University School of Public Health, Kampala, Uganda.
Ronald H GrayRakai Health Sciences Program, Entebbe, Uganda; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Fred NalugodaRakai Health Sciences Program, Entebbe, Uganda.
Nelson K SewankamboRakai Health Sciences Program, Entebbe, Uganda; Makerere University School of Medicine, Kampala, Uganda.
Lisa NelsonCenters for Disease Control and Prevention, Entebbe, Uganda.
Lisa A MillsCenters for Disease Control and Prevention, Entebbe, Uganda.
Donna KabatesiCenters for Disease Control and Prevention, Entebbe, Uganda.
Stella AlamoCenters for Disease Control and Prevention, Entebbe, Uganda.
Caitlin E KennedySocial and Behavioral Interventions Program, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Aaron A R TobianRakai Health Sciences Program, Entebbe, Uganda; Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
John S SantelliDepartment of Population and Family Health, Columbia Mailman School of Public Health, New York, NY, USA.
Anna Mia EkströmDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Helena NordenstedtDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Thomas C QuinnDivision of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Laboratory of Immunoregulation, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Maria J WawerRakai Health Sciences Program, Entebbe, Uganda; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Steven J ReynoldsDivision of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA; Laboratory of Immunoregulation, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Rakai Health Sciences Program · UGCenters for Disease Control and Prevention · UGJohns Hopkins University · USMakerere University · UGFrederick National Laboratory for Cancer Research · USKarolinska Institutet · SEKarolinska University Hospital · SENational Institutes of Health · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
Methods for Reducing Spatial Uncertainty and Bias in Disease SurveillanceR01AI102939 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LESSLER, JUSTIN · 2013 to 2017
$4.6M
Structural and Social Transitions Among Adolescents in Rakai (SSTAR)R01HD091003 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SANTELLI, JOHN S. · 2017 to 2021
$3.7M
The role of penile bacteria and inflammation in HIV susceptibility; Rakai, UgandaR01AI123002 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI LIU, CINDY · 2016 to 2020
$3.3M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
Hard-to-Reach Populations: Implications for Ending the AIDS EpidemicR01AI143333 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2019 to 2022
$2.4M
HIV Incidence, Transmission Dynamics and Combination HIV Prevention: Rakai UgandaR01AI110324 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2014 to 2016
$2.4M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
Multidisciplinary Research Training to Understand and Reduce HIV Incidence in UgandaD43TW010557 · FIC · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2018 to 2022
$1.6M
Understanding HIV risk and service use in hotspot Ugandan fishing communitiesR01MH105313 · NIMH · JOHNS HOPKINS UNIVERSITY · PI KENNEDY, CAITLIN E · 2015 to 2017
$1.1M
CCR NIH HHS HHSN261200800001CFIC NIH HHS D43 TW010557NCI NIH HHS HHSN261200800001ENIAID NIH HHS K01 AI125086NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI102939NIAID NIH HHS R01 AI110324NIAID NIH HHS R01 AI123002NIAID NIH HHS R01 AI128779NIAID NIH HHS R01 AI143333NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NICHD NIH HHS R01 HD091003NIMH NIH HHS R01 MH105313NIMH NIH HHS R01 MH107275
6 · The paper itself

Abstract

backgroundTargeting combination HIV interventions to locations and populations with high HIV burden is a global priority, but the impact of these strategies on HIV incidence is unclear. We assessed the impact of combination HIV interventions on HIV incidence in four HIV-hyperendemic communities in Uganda.

methodsWe did an open population-based cohort study of people aged 15-49 years residing in four fishing communities on Lake Victoria. The communities were surveyed five times to collect self-reported demographic, behavioural, and service-uptake data. Free HIV testing was provided at each interview, with referral to combination HIV intervention services as appropriate. From November, 2011, combination HIV intervention services were rapidly expanded in these geographical areas. We evaluated trends in HIV testing coverage among all participants, circumcision coverage among male participants, antiretroviral therapy (ART) coverage and HIV viral load among HIV-positive participants, and sexual behaviours and HIV incidence among HIV-negative participants.

findingsFrom Nov 4, 2011, to Aug 16, 2017, data were collected from five surveys. Overall, 8942 participants contributed 20 721 person-visits; 4619 (52%) of 8942 participants were male. HIV prevalence was 41% (1598 of 3870) in the 2011-12 baseline survey and declined to 37% (1740 of 4738) at the final survey (p<0·0001). 3222 participants who were HIV-negative at baseline, and who had at least one repeat visit, contributed 9477 person-years of follow-up, and 230 incident HIV infections occurred. From the first survey in 2011-12 to the last survey in 2016-17, HIV testing coverage increased from 68% (2613 of 3870) to 96% (4526 of 4738; p<0·0001); male circumcision coverage increased from 35% (698 of 2011) to 65% (1630 of 2525; p<0·0001); ART coverage increased from 16% (254 of 1598) to 82% (1420 of 1740; p<0·0001); and population HIV viral load suppression in all HIV-positive participants increased from 34% (546 of 1596) to 80% (1383 of 1734; p<0·0001). Risky sexual behaviours did not decrease over this period. HIV incidence decreased from 3·43 per 100 person-years (95% CI 2·45-4·67) in 2011-12 to 1·59 per 100 person-years (95% CI 1·19-2·07) in 2016-17; adjusted incidence rate ratio (IRR) 0·52 (95% CI 0·34-0·79). Declines in HIV incidence were similar among men (adjusted IRR 0·53, 95% CI 0·30-0·93) and women (0·51, 0·27-0·96). The risk of incident HIV infection was lower in circumcised men than in uncircumcised men (0·46, 0·32-0·67).

interpretationRapid expansion of combination HIV interventions in HIV-hyperendemic fishing communities is feasible and could have a substantial impact on HIV incidence. However, incidence remains higher than HIV epidemic control targets, and additional efforts will be needed to achieve this global health priority.

fundingThe National Institute of Mental Health, the National Institute of Allergy and Infectious Diseases, the National Institute of Child Health and Development, the National Cancer Institute, the National Institute for Allergy and Infectious Diseases Division of Intramural Research, Centers for Disease Control and Prevention Uganda, Karolinska Institutet, and the Johns Hopkins University Center for AIDS Research.

Indexed as

AdolescentAdultAnti-HIV AgentsCircumcision, MaleCohort StudiesEpidemicsFemaleHIV InfectionsHumansIncidenceMaleMiddle AgedProspective StudiesRural PopulationUgandaYoung AdultAnti-HIV Agents

Identifiers

PMID31533894
PMCPMC6832692
OpenAlexW2972876705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.